Reduction of Low-value Prescribing Through Audit and Feedback

NCT07336550 — Not applicable, Not yet recruiting, 540 participants, Basque Health Service

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

AFFAP Trial: The Comparative Evaluation of Audit and Feedback-based De-implementation Strategies to Reduce Low-value Prescribing in Primary Care in Patients Over 65 Years of Age.

RegistryNCT07336550, acronym AFFAP
StatusNot yet recruiting
PhaseNot applicable
Study typeInterventional; randomized, crossover, masking: double, health services research
Enrollment540 (Estimated)
SponsorBasque Health Service (Other gov); collaborators: Biobizkaia Health Research Institute, Basque Government Department of Public Health, European Union, Carlos III Health Institute (ISCIII), Spain
ConditionsInappropriate Prescribing, Implementation Science, Behavioral Sciences
InterventionsUsual AF, Facilitated AF (Behavioral)
Datesstart 2026-06-01 (estimated), primary completion 2027-06-01 (estimated), completion 2027-12-01 (estimated), first posted 2026-01-13, last updated 2026-05-13
Locations1 site in Spain

Related Papers Related Patents Related Grants Related Experts
All trials for Inappropriate Prescribing All trials for Implementation Science All trials of Usual AF All trials of Facilitated AF

-Summary

The objective is to estimate the effect attributable to a primary care pharmacist-led audit and feedback (AF) strategy compared to the currently used AF strategy as a management tool to evaluate healthcare performance focusing on processes and outcomes, for reducing the rate of patients over 65 years of age with potentially inappropriate prescribing (PIP) of benzodiazepines, proton pump inhibitors and opioids.

A closed-cohort stepped-wedge cluster-randomised trial will be conducted in nine PC centres from Barakaldo-Sestao Integrated Health Organization, Basque Health Service (Osakidetza). All health centre clusters will start under the control condition, and after an initial study period of 4 months in the control phase, one centre per step at 1-month intervals will be randomly assigned to crossover to the intervention, under which they will be exposed to an additional component of AF, namely, primary care pharmacist-led facilitation.

Mixed-methods analysis will be performed, gathering quantitative data to assess the results of the implementations at health centre and clinician levels, and qualitative data to assess the feasibility and perceived impact of the de-implementation strategies from the clinicians' perspective, and explore the experience and satisfaction of patients regarding the healthcare received.

This study will provide useful knowledge on the effect attributable to a more intensive AF strategy (facilitated AF) compared to standard procedures of AF reports, and of the characteristics of AF that are most effective.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
ControlActive comparatorBehavioral: Usual AFAll health centre clusters will start under the control condition
InterventionExperimentalBehavioral: Usual AF; Behavioral: Facilitated AFone centre per step at 1-month intervals will be randomly assigned to crossover to the intervention
  • Usual AF (Behavioral): The strategy currently used as a management tool to evaluate healthcare performance focusing on processes and outcomes, as part of Osakidetza's operating contract: provision of AF, sent to PC centres every 4 months with data on overall rates of PIP, lists of patients over 65 years old who have a potentially inappropriate prescription of at least one of the drugs of interest, and provision of support materials related to appropriate prescribing and recommendations on deprescribing.
  • Facilitated AF (Behavioral): Based on a facilitation component delivered by PC pharmacy staff. Specifically, the PC pharmacists will conduct a facilitation session with the centre's clinicians in which they will review the magnitude of PIP in the centre (PIP rates), appropriateness/inappropriateness criteria, and guidelines to encourage deprescribing, and draw up an action plan at clinician and centre levels.

+Outcome measures

Primary outcomes

  • Primary effectiveness: Proportion of patients with deprescribing or tapering of any of the PIP [From baseline to 13 months]: proportion of patients for whom appropriateness is achieved, either through deprescribing or tapering (for example, dose reduction) of any of the drugs potentially inappropriately prescribed in the patients included in the clusters.

Secondary outcomes

  • Secondary effectiveness: Proportion of patients with deprescribing or tapering for each PIP [From baseline to 13 months]: proportion of patients in whom appropriateness is achieved for each of the potentially inappropriately prescribed drugs assessed separately
  • Secondary Effectiveness: Rate of new PIP [From baseline to 13 months]: Rate of new PIP among patients over 65 years old seeking medical care during the study period
  • Adoption: Percentage of General Practitioners who agree to receive the active components of the strategies [From baseline to 13 months]: Percentage of doctors, out of the total number invited to participate at the start of the intervention, who agree to receive the active components of the strategies, as well as the characteristics of those who do and do not agree to participate.
  • Degree of implementation fidelity [From baseline to 13 months]: The degree of fidelity with which each strategy has been implemented compared to what was originally planned will be evaluated. For this, the implementation process and any adaptations made to the strategies or their active components will be recorded and subsequently described. Furthermore, we will evaluate the degree of exposure of GPs to the strategies.
  • General Practitioners´ perception of the feasibility and acceptability [From baseline to 19 months]: GPs perception of the feasibility and acceptability of the deprescribing strategy based on the AF to adapt/reduce their practice of unnecessary pharmacological prescribing.

+Eligibility

Sex: All, ages: 65 Years to any, accepts healthy volunteers

PRIMARY CARE CENTERS IN THE BARAKALDO-SESTAO INTEGRATED HEALTHCARE ORGANISATION OF OSAKIDETZA-BASQUE HEALTH SERVICE:

Inclusion Criteria:

* collaboration is achieved from at least 51% of the General Practitioners (GP) or at least 4 GPs
* At least 60 patients aged 65 years or older on at least one of the drugs of interest that may be potentially inappropriately prescribed

Exclusion Criteria:

* N/A

PATIENTS ASSIGNED TO THE PARTICIPATING PC CENTERS:

Inclusion Criteria:

* Patients over 65 years of age with any of the following unsuitability criteria:
* PIP of benzodiazepines: patients on benzodiazepines for more than 3 months
* PIP of proton pump inhibitors: patients on proton pump inhibitors for more than 8 weeks without a diagnosed gastrointestinal disease and with no long-term prescription of gastrotoxic drugs.
* PIP of opioids: patients on opioids for non-cancer pain for more than 3 months.

Exclusion Criteria:

* Patients who, in the opinion of the general practitioner, are not suitable candidates for tapering or discontinuation of the potentially inappropriately prescribed drug
* Patients residing in care homes
* Patients receiving palliative care

+Locations (1)

FacilityCityCountryStatus
Primary Care Research Unit of BizkaiaBarakaldo, BizkaiaSpain